CRAIG LEE SLINGLUFF

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. ncbi request reprint Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 22:4474-85. 2004
  2. ncbi request reprint Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 13:6386-95. 2007
  3. pmc A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 19:4228-38. 2013
  4. pmc Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)
    Craig L Slingluff
    University of Virginia, Charlottesville, VA 22908, USA
    Clin Cancer Res 19:3611-20. 2013
  5. pmc Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function
    Walter C Olson
    Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
    J Transl Med 9:26. 2011
  6. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
  7. pmc Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
    Jochen T Schaefer
    Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
    J Transl Med 8:79. 2010
  8. pmc The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines
    Donna H Deacon
    Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
    BMC Cancer 8:360. 2008
  9. pmc Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 26:4973-80. 2008
  10. ncbi request reprint Peptide and dendritic cell vaccines
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 12:2342s-2345s. 2006

Collaborators

Detail Information

Publications49

  1. ncbi request reprint Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 22:4474-85. 2004
    ....
  2. ncbi request reprint Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 13:6386-95. 2007
    ..Because melanomas commonly evade immune recognition by selective antigen loss, optimization of melanoma vaccines may require development of more complex multipeptide vaccines...
  3. pmc A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 19:4228-38. 2013
    ..This multicenter randomized trial was designed to evaluate whether melanoma helper peptides augment cytotoxic T lymphocyte (CTL) responses to a melanoma vaccine and improve clinical outcome in patients with advanced melanoma...
  4. pmc Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)
    Craig L Slingluff
    University of Virginia, Charlottesville, VA 22908, USA
    Clin Cancer Res 19:3611-20. 2013
    ..A CTEP-sponsored phase II trial was conducted to evaluate safety and clinical activity of combination therapy with CCI-779 (temsirolimus) and bevacizumab in patients with advanced melanoma...
  5. pmc Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function
    Walter C Olson
    Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
    J Transl Med 9:26. 2011
    ..The effect of temperature during storage and shipment of peripheral blood on subsequent processing, recovery, and function of lymphocytes is understudied and represents the focus of this study...
  6. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  7. pmc Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis
    Jochen T Schaefer
    Human Immune Therapy Center, University of Virginia, Charlottesville, VA, USA
    J Transl Med 8:79. 2010
    ..We hypothesized that a vaccine in incomplete Freund's adjuvant (IFA) would increase dermal Th1 and Tc1-lymphocytes and mature DCs, but that repeated vaccination may increase regulatory cells...
  8. pmc The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines
    Donna H Deacon
    Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
    BMC Cancer 8:360. 2008
    ..We have, therefore, investigated ultraviolet (UV)-irradiation as a possible adjunct to, or replacement for gamma-irradiation...
  9. pmc Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Clin Oncol 26:4973-80. 2008
    ..Source proteins for these peptides include MAGE proteins, MART-1/MelanA, gp100, and tyrosinase...
  10. ncbi request reprint Peptide and dendritic cell vaccines
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 12:2342s-2345s. 2006
    ....
  11. ncbi request reprint Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, 22908, USA
    J Clin Oncol 21:4016-26. 2003
    ..To determine clinical and immunologic responses to a multipeptide melanoma vaccine regimen, a randomized phase II trial was performed...
  12. pmc Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines
    Craig L Slingluff
    Department of Surgery, Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Ann Surg Oncol 15:3538-49. 2008
    ....
  13. pmc Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines
    Craig L Slingluff
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 33:630-8. 2010
    ..Despite the necessarily retrospective nature of the analysis and limitations of multiple comparisons, our summary data support the use of IFA-VG as an adjuvant with multipeptide vaccines in melanoma patients...
  14. pmc Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Clin Oncol 29:2924-32. 2011
    ....
  15. ncbi request reprint Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes
    C L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, 22908, USA
    Clin Cancer Res 7:3012-24. 2001
    ..Although this Phase I study was not intended to evaluate clinical benefit, the excellent survival of patients on this protocol suggests the possibility of a benefit that should be assessed in future studies...
  16. pmc The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
    Craig L Slingluff
    Human Immune Therapy Center, University of Virginia, Charlottesville, USA
    Cancer J 17:343-50. 2011
    ..To apply these new approaches optimally, it will be critical to study their effects in the context of defined antigens, for which peptide vaccines are optimal...
  17. pmc The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides
    Rebecca C Harris
    Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 35:78-88. 2012
    ..Further study of the physiology of the vaccine site microenvironment promises to identify opportunities for enhancing cancer vaccine efficacy by modulating immune activation and regulation at the site of vaccination...
  18. ncbi request reprint Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
    G V Yamshchikov
    Division of Surgical Oncology, Department of Surgery, University of Virginia HSC, Charlottesville, VA 22908, USA
    Int J Cancer 92:703-11. 2001
    ..This combination of an immunogenic vaccine strategy with a sensitive analysis of CTL responses demonstrates the potential for inducing and detecting anti-tumor immune responses in the majority of melanoma patients...
  19. pmc gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells
    L S Kierstead
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Br J Cancer 85:1738-45. 2001
    ..Based on these data, these epitopes may serve as potent vaccine components to promote clinically-relevant Th1-type CD4+ T cell effector function in situ...
  20. ncbi request reprint Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens
    C L Slingluff
    Department of Surgery, University of Virginia, Charlottesville 22906, USA
    Cancer Immunol Immunother 48:661-72. 2000
    ....
  21. pmc Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy
    M M Moore
    Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, Virginia 22908 0709, USA
    Ann Surg 231:877-82. 2000
    ....
  22. ncbi request reprint Patient preferences for adjuvant interferon alfa-2b treatment
    K L Kilbridge
    Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, VA 22908 0821, USA
    J Clin Oncol 19:812-23. 2001
    ..Utilities are measures of preference for a particular health state on a scale of 0 (death) to 1 (perfect health)...
  23. ncbi request reprint Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations
    G Yamshchikov
    Department of Surgery, University of Virginia Health Sciences Center and Cancer Center, Charlottesville 22908, USA
    Clin Cancer Res 7:909s-916s. 2001
    ..These data provide an estimate of the level of CTL response that may be associated with protection from tumor recurrence...
  24. ncbi request reprint CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease
    Irene M Mullins
    Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, Virginia 22908 1360, USA
    Cancer Res 64:7697-701. 2004
    ..These findings support the hypothesis that the host immune system affects cancer progression and control, and that measures of CCR status of circulating lymphocytes may have prognostic value...
  25. doi request reprint A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
    Kimberly A Chianese-Bullock
    Department of Surgery, Division of Surgical Oncology, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 31:420-30. 2008
    ....
  26. ncbi request reprint Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines
    V Anne Westbrook
    Department of Cell Biology, Center for Research in Contraceptive and Reproductive Health, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 10:101-12. 2004
    ..Significantly, the incidence of SPAN-X-positive immunostaining was greatest in the more aggressive skin tumors, particularly in distant, nonlymphatic metastatic melanomas...
  27. ncbi request reprint Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes
    Kevin T Hogan
    Department of Surgery, University of Virginia, Box 801359, Charlottesville, VA 22908, USA
    Immunol Lett 90:131-5. 2003
    ..The peptide may also be useful as a research tool for evaluating spontaneous anti-tumor immune responses in patients with melanoma...
  28. ncbi request reprint Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision
    Heather L Evans
    Department of Surgery, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    Ann Surg Oncol 10:416-25. 2003
    ..Patients have traditionally been considered candidates for sentinel node biopsy (SNBx) only at the time of wide local excision (WLE). We hypothesized that patients with prior WLE may also be staged accurately with SNBx...
  29. ncbi request reprint MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma
    Tomohide Tatsumi
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Cancer Res 9:947-54. 2003
    ..These data suggest that MAGE-6-derived epitopes could serve as useful vaccine candidate components and may provide an immune-monitoring index of clinically important Th1-type immunity in patients with renal cell carcinoma or melanoma...
  30. ncbi request reprint Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review
    Liana Abramova
    Department of Surgery, University of Virginia Health Science Center, Charlottesville, Virginia 22906, USA
    Ann Surg Oncol 9:840-6. 2002
    ..However, prophylactic lymphadenectomy has not been shown to improve survival of melanoma patients. We wanted to determine the feasibility of sentinel lymph node biopsy in patients with female urogenital melanoma as a staging procedure...
  31. ncbi request reprint Problems in the interpretation of apparent "radial growth phase" malignant melanomas that metastasize
    Liana Abramova
    Department of Pathology, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA
    J Cutan Pathol 29:407-14. 2002
    ..Vertical growth phase (VGP) lesions have the potential to metastasize, but radial growth phase (RGP) melanomas are believed to lack competence for metastasis...
  32. ncbi request reprint Immunotherapy for melanoma
    Christina J Kim
    Department of Surgery, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Cancer Control 9:22-30. 2002
    ..Interferon-a has been approved for adjuvant treatment of stage III melanoma with improved survival. New and more innovative approaches with improved efficacy are needed...
  33. ncbi request reprint The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes
    Sara J Adair
    Department of Surgery and the Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 31:7-17. 2008
    ..These results indicate that TAG-derived peptides may be good components of a therapeutic vaccine designed to target melanoma and a variety of epithelial cell-derived malignancies...
  34. ncbi request reprint Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma
    Kevin T Hogan
    Department of Surgery, University of Virginia, and Argonex, Inc, Charlottesville, Virginia, USA
    Cancer Res 64:1157-63. 2004
    ..The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of melanoma and perhaps other cancers...
  35. ncbi request reprint Competition among peptides in melanoma vaccines for binding to MHC molecules
    Lee W Thompson
    Department of Surgery, Division of Surgical Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
    J Immunother 27:425-31. 2004
    ..These data suggest that CTLs can respond to multiple peptides presented on the same antigen-presenting cells and justify further investigation, in clinical trials, of multiple-peptide cancer vaccines...
  36. ncbi request reprint Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members
    Kevin T Hogan
    Department of Surgery, University of Virginia, Box 801359, Charlottesville, VA 22908, USA
    Cancer Immunol Immunother 54:359-71. 2005
    ....
  37. ncbi request reprint Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine
    Elizabeth M H Woodson
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
    J Immunother 27:380-8. 2004
    ..The hematologic effects of this therapy were delayed in time between the two treatment groups, without dramatic differences in magnitude, which suggests minimal modulation of the IL-2 toxicity by components of the vaccine...
  38. ncbi request reprint MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology, University of Virginia Health System, Charlottesville, VA 22908, USA
    J Immunol 174:3080-6. 2005
    ..Cancer-testis Ags are expressed in multiple types of cancer; thus the MAGE-A1(96-104) and MAGE-A10(254-262) peptides may be considered for inclusion in vaccines against cancers of other histologic types, in addition to melanoma...
  39. ncbi request reprint Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients
    William Chad Cragun
    School of Medicine, University of Virginia Health System, Charlottesville, VA, USA
    Cancer Immunol Immunother 54:1095-105. 2005
    ..Paradoxically, CTL responses were diminished in patients after 2 weeks of IL-2. We hypothesized that changes in the cytokine milieu may have contributed to this result...
  40. pmc Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2
    Kerrington R Molhoek
    Department of Surgery, Division of Surgical Oncology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA
    Cancer Res 68:4392-7. 2008
    ....
  41. ncbi request reprint Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma
    Galina V Yamshchikov
    Department of Surgery, University of Virginia, Charlottesville, 22908, USA
    J Immunol 174:6863-71. 2005
    ....
  42. ncbi request reprint Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2
    Kimberly A Chianese-Bullock
    Department of Surgery Division of Surgical Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
    J Immunother 28:412-9. 2005
    ..However, careful monitoring for autoimmune toxicities should be incorporated in future clinical studies incorporating low-dose IL-2...
  43. ncbi request reprint Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients
    Anneke T Schroen
    Department of Surgery, University of Virginia, Charlottesville, VA 22908 0709, USA
    J Clin Oncol 23:7074-80. 2005
    ..Treatment access underlies quality cancer care. We hypothesize that mastectomy rates in a rural state are independently influenced by distance to radiation therapy (XRT) and by changing XRT access through opening new facilities...
  44. ncbi request reprint Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity
    Lee W Thompson
    Department of Surgery, University of Virginia, Charlottesville 22908, USA
    J Immunother 27:177-83. 2004
    ..These findings suggest general strategies for enhancing the antigenicity of other peptides containing similar amino acids in their sequence...
  45. ncbi request reprint Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells
    Chien Chung Chang
    Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Biol Chem 281:18763-73. 2006
    ....
  46. ncbi request reprint Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling
    Jonathan T Huntington
    Norris Cotton Cancer Center, Departments of Physiology, Medicine, and Biochemistry, Dartmouth Medical School, Lebanon NH 03756, USA
    J Biol Chem 279:33168-76. 2004
    ..Thus, constitutive activation of this MAPK pathway not only promotes the increased proliferation of melanoma cells but is also important for the acquisition of an invasive phenotype...
  47. ncbi request reprint Innovations and challenges in melanoma: summary statement from the first Cambridge conference
    Michael B Atkins
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 12:2291s-2296s. 2006
    ....
  48. ncbi request reprint Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
    David H Munn
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Science 297:1867-70. 2002
    ..IDO+ DCs could also be readily detected in vivo, which suggests that these cells may represent a regulatory subset of APCs in humans...

Research Grants26

  1. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2007
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. ..
  2. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    Craig Slingluff; Fiscal Year: 2007
    ....
  3. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2009
    ....
  4. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    ....
  5. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    Craig Slingluff; Fiscal Year: 2009
    ....
  6. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    ....
  7. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    ....
  8. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2007
    ....
  9. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2006
    ....
  10. HLA-A2 ASSOCIATED PEPTIDE EPITOPES FOR CTL ON MELANOMA
    Craig Slingluff; Fiscal Year: 1999
    ....
  11. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2002
    ..The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types. ..
  12. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2003
    ..The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types. ..
  13. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2004
    ..The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types. ..
  14. MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF
    Craig Slingluff; Fiscal Year: 2004
    ..abstract_text> ..
  15. VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES
    Craig Slingluff; Fiscal Year: 2004
    ....
  16. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2005
    ..The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types. ..
  17. MULTI-EPITOPE MELANOMA VACCINES FOR CD4 AND CD8 T-CELLS
    Craig Slingluff; Fiscal Year: 2005
    ....
  18. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    Craig Slingluff; Fiscal Year: 2006
    ....
  19. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2006
    ..The work proposed in this application will set the stage for randomized trials comparing optimized peptide vaccines to optimized vaccines of other types. ..
  20. MELANOMA VACCINES USING MHC-ASSOCIATED PEPTIDES
    Craig Slingluff; Fiscal Year: 2009
    ....